MedTrace Logo

Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)

NCT03745378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1881

Last updated 2019-12-06

No results posted yet for this study

Summary

The incidence of secondary cancer (SC) in patients with myeloproliferative neoplasms (MPN) is high and comparable to that of thrombosis. However, the identification of patient subgroups that might be at increased susceptibility of developing SC has not been systematically addressed. This international case-control study (MPN-K) is aimed to elucidate the prognostic role of JAK2V617F mutation in predicting the occurrence of SC in patients with classical MPN, polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF)

Conditions

Interventions

OTHER

JAK2V617F mutation

JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,

Sponsors & Collaborators

  • FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

    lead OTHER

Principal Investigators

  • Tiziano Barbui, Prof · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

  • Guido Finazzi, Dr · ASST-Papa Giovanni XXIII

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2018-07-07
Completion
2018-09-30

Countries

  • Czechia
  • Germany
  • Israel
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03745378 on ClinicalTrials.gov